Skip to content
SalamTechs
العربيةBusiness services

Biobeat develops wearable monitoring technology using optical sensors.

Introduce me to Biobeat
Biobeat website sharing image

Image source: company website sharing image

Founders & company facts

Sources reviewed:

Reported cumulative funding

$68,600,000 · Source

This index includes companies with publicly reported total funding up to US$150 million. This is a reported total, not valuation, the latest round size or confirmation of an open round. Funding reviewed: .

Documented founding team

Founded
2016Source
Reported Israeli location
Petah TikvaSource
Team range in directory
11-50Source
Reported business model
B2B, B2B2CSource

Selected disclosed financing

Selected transactions, with dates, funding types and reported participants.

  1. Jan 2026$50MSeries B
    Named participants

    Ally Bridge Group · OrbiMed

    Source
  2. Sept 2023$7MSeries A
    Named participants

    Best Buy Health

    Source

Company overview

Product & customers

Biobeat develops wearable monitoring technology using optical sensors. Its offering includes cuffless blood-pressure monitoring and related physiological measurements, with reports designed to support clinical evaluation.

Commercial potential · editorial analysis

The commercial opportunity is supporting repeated monitoring outside a single clinic measurement, with potential distribution through healthcare providers and monitoring programmes. Investors should distinguish paid use and renewals from pilots, and examine how sales and delivery costs change as deployments expand.

What to validate

Diligence should focus on indication-specific regulatory scope, comparison with reference measurements, adherence and performance across diverse patient groups. Evidence should come from representative customer deployments, with costs, limitations and failure cases reported alongside successful results.

Explore the company website

Product source reviewed on . Company source